Interventional oncology for hepatocellular carcinoma

详细信息    查看全文

• 作者：Julien Delicque^a ; Mathieu Boulin^b ; Boris Guiu^a ; ^{b-guiu@chu-montpellier.fr" class="auth_mail" title="E-mail the corresponding author} ; Jean-Pierre Pelage^a ; Laure Escal^a ; Valentina Schembri^a ; Eric Assenat^c ; Audrey Fohlen^d ; ^{fohlen@cyceron.fr" class="auth_mail" title="E-mail the corresponding author}
• 刊名：Clinics and Research in Hepatology and Gastroenterology
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：40
• 期：5
• 页码：530-537
• 全文大小：487 K

文摘

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and is increasing in incidence. The overall prognosis of patients with liver cancer is poor. The Barcelona Clinic Liver Cancer (BCLC) classification in 5 stages is endorsed by European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Disease (AASLD). This classification is recommended for treatment allocation. Because a small proportion of patients are suitable for curative surgical treatment, various locoregional therapies are widely used to manage patients with HCC. The image-guided therapies, also called interventional radiology or interventional oncology (IO) techniques consisted in percutaneous or endovascular approach. This article reviews the different IO treatments available in HCC patients and the strength of the data.